Armata Pharmaceuticals, Inc. — Earnings Release 2007

Mar 29, 2007

8-K 1 v069775_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 29, 2007

| Targeted
Genetics Corporation |
| --- |
| (Exact
name of registrant as specified in its
charter) |

Washington	0-23930	91-1549568
(State
or other jurisdiction of
incorporation)	(Commission
File Number)	(IRS
Employer Identification
No.)

| 1100
Olive Way, Suite 100, Seattle, Washington | 98101 |
| --- | --- |
| (Address
of principal executive offices) | (Zip
Code) |

Registrant's telephone number, including area code (206) 623-7612

| Not
Applicable |
| --- |
| (Former
name or former address if changed since last
report) |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On March 29, 2007, Targeted Genetics Corporation announced financial results for the quarter and fiscal year ended December 31, 2006. A copy of the press release related to this announcement is attached as Exhibit 99.1 and is incorporated into this current report by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibits.

99.1 Press Release of Targeted Genetics Corporation dated March 29, 2007

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Targeted
Genetics Corporation | |
| --- | --- |
| By: | /s/ David
J.
Poston |
| | David
J. Poston Vice
President Finance and Chief
Financial Officer |

Dated: March 29, 2007

3

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Press
Release of Targeted Genetics Corporation dated March 29,
2007

4